RPE

HUIDAGENE THERAPEUTICS ANNOUNCES IND ACTIVE FOR THE MULTINATIONAL TRIAL OF HG004 TO TREAT INHERITED BLINDNESS

Retrieved on: 
Saturday, January 28, 2023
Retinal pigment epithelium, IND, DSM-IV codes, Visual impairment, IIT, CRISPR, Human, Retina, Entrepreneurship, Partnership, Paratriathlon, FDA, CMC, Patient, Risk, Food, AAV2, AAV, Food and Drug Administration, RPE, Week, Pharmaceutical industry, Vaccine, RPE65, US FDA

SHANGHAI and CLINTON, N.J., Jan. 28, 2023 /PRNewswire/ -- HuidaGene Therapeutics (HuidaGene), a clinical-stage biotechnology company developing CRISPR-based programmable genomic medicine, announces that the US.

Key Points: 
  • SHANGHAI and CLINTON, N.J., Jan. 28, 2023 /PRNewswire/ -- HuidaGene Therapeutics (HuidaGene), a clinical-stage biotechnology company developing CRISPR-based programmable genomic medicine, announces that the US.
  • "We are thrilled to have received the IND clearance of our HG004 program from US FDA, marking our first IND clearance as a company and our first retinal disorder program to reach clinical development stage," said Xuan Yao, Ph.D., Co-founder and Chief Executive Officer of HuidaGene.
  • The goal of the HG004 program is to develop a one-time, non-AAV2 gene replacement therapy to restore, treat, and prevent blindness of children and adults with severe visual impairment or blindness due to RPE65 mutation-associated retinopathies globally."
  • Investigational HG004 is a novel ophthalmic injection that is being developed to treat RPE65 retinopathies.

Stargardt Disease Drug Pipeline Research Report 2022: Insights on 18+ Xompanies and 20+ Pipeline Drugs - Therapeutic Assessments by Product Type, Stage, Route of Administration, and Molecule Type - ResearchAndMarkets.com

Retrieved on: 
Wednesday, December 14, 2022
Health, Biotechnology, Therapy, NDA, Route, RPE, Triglyceride, Lipoprotein, Administration, News, Clinical trial, Route of administration, Eye, Tissue, STRA6, Discovery, RBP4, Vitamin A, Acquisition, Medical device, Pharmaceutical industry, Stargardt disease

This "Stargardt disease Pipeline Insight, 2022" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Stargardt disease pipeline landscape.

Key Points: 
  • This "Stargardt disease Pipeline Insight, 2022" report provides comprehensive insights about 18+ companies and 20+ pipeline drugs in Stargardt disease pipeline landscape.
  • It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type.
  • The assessment part of the report embraces, in depth Stargardt disease commercial assessment and clinical assessment of the pipeline products under development.
  • Stargardt disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Cognition Therapeutics Presents Scientific Rationale, Clinical Biomarker and Preclinical Data supporting a Phase 2 Clinical Trial with CT1812 in Geographic Atrophy Secondary to Dry AMD

Retrieved on: 
Thursday, December 1, 2022
Molecule, COVID-19, Neurodegeneration, RPE, Dementia, Severe cognitive impairment, Administration, Geographic atrophy, Laboratory, Potency (pharmacology), Food, DLB, Cell, Retinal, Risk, Therapy, Degenerative disease, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Drusen, Macular degeneration, Retina, IPSC, Protein, Inflammation, Central nervous system, Disease, Cognition, AMD, POS, Alzheimer's disease, Lewy body, GA, Intellectual property, Phase II, Vance DeGeneres, Traffic barrier, Securities & Exchange Commission of Pakistan, Oxidative stress, Eye, Biology, Neuron, Dry, FDA, Pharmaceutical industry, Vaccine

Complement inhibition has shown potential in clinical trials but must be given via intravitreal injection to each affected eye.

Key Points: 
  • Complement inhibition has shown potential in clinical trials but must be given via intravitreal injection to each affected eye.
  • CT1812 is an experimental oral sigma-2 (-2) receptor modulator currently in Phase 2 clinical trials for both Alzheimer's disease and dementia with Lewy bodies (DLB).
  • The proteomic analyses from our clinical studies in neurodegenerative disease were instrumental in identifying dry AMD as an indication of interest, explained Mary Hamby, Ph.D. , VP of biology at Cognition Therapeutics.
  • We are currently investigating our lead candidate CT1812 in clinical programs in Alzheimers disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD).

Apex Physics Partners (APP) Expands Its National Footprint with New Partnerships in Arizona and Florida

Retrieved on: 
Wednesday, November 16, 2022
Hospitals, General Health, Health, Other Health, Marketing, Physics, Insurance, Information technology, Fear, Fusion, RPE, APP, Growth, Health, Google Images, Patient, Medical device, Medical imaging

Apex Physics Partners (APP), the largest outsourced medical physics services company in North America, today announced that two new companies, Fusion Physics, LLC in Tampa, Florida, and Radiation Physics & Engineering, Inc (RPE) in Phoenix, Arizona, are now part of its network.

Key Points: 
  • Apex Physics Partners (APP), the largest outsourced medical physics services company in North America, today announced that two new companies, Fusion Physics, LLC in Tampa, Florida, and Radiation Physics & Engineering, Inc (RPE) in Phoenix, Arizona, are now part of its network.
  • Headquartered in Phoenix, RPE offers diagnostic medical physics services to healthcare and environmental companies across Arizona, New Mexico and the Southwest.
  • Our purpose is to enable healthier communities, and our latest partnerships demonstrate our ongoing commitment to this goal, said Michael Curry, CEO of Apex Physics Partners.
  • Apex Physics Partners ( http://www.apexphysicspartners.com ) is the largest outsourced medical physics services organization in North America, offering diagnostic and therapy medical physics services to large hospital systems, healthcare facilities, imaging centers and cancer care groups throughout the U.S.

NOVA Chemicals Launches 100% Post-Consumer Mechanically Recycled Polyethylene Resin

Retrieved on: 
Tuesday, October 25, 2022
Commercial, Nova Chemicals, Mubadala Investment Company, LinkedIn, Emirate, Safety, AB, Growth, Goal, Center, NOVA, Responsible Care, Climate change, PE, Leadership, Happiness, GLOBE, Recycling, Health, Association, Carbon, RPE, Performance Application Programming Interface, Nova, Thermoplastic

CALGARY, AB, Oct. 25, 2022 (GLOBE NEWSWIRE) -- NOVA Chemicals Corporation (NOVA Chemicals), a leading producer of polyethylene resins, announced the launch of its new, mechanically recycled polyethylene resin: EX-PCR-NC4.

Key Points: 
  • CALGARY, AB, Oct. 25, 2022 (GLOBE NEWSWIRE) -- NOVA Chemicals Corporation (NOVA Chemicals), a leading producer of polyethylene resins, announced the launch of its new, mechanically recycled polyethylene resin: EX-PCR-NC4.
  • NOVA Chemicals rPE is sourced from distribution center flexible film, which includes a blend of back-of-store stretch and front-of-store consumer drop off.
  • NOVA Chemicals continues to demonstrate leadership in providing sustainable polyethylene solutions, and we look forward to additional growth in this space.
  • The NOVA Chemicals logo is a registered trademark of NOVA Brands Ltd.; authorized use.

BioChange's ReGum™ has been scientifically proven to heal gum recession disease

Retrieved on: 
Thursday, September 22, 2022
Debridement, ECM, Inflammation, Time, Safety, Trial of the century, Matrix, Human, Plaque, Tooth, Dog, RPE, Gingivitis, Regeneration, Periodontal disease, Bleeding, CEO, Technology, Cell, Tissue, Collagen, Degenerative disease, Regummed stamp, Research, AMD, Dentistry, Silk, Frontiers

YOKNEAM ILLIT, Israel, Sept. 22, 2022 /PRNewswire/ -- Israeli startup BioChange, which has developed a breakthrough technology for tissue regeneration, was able to treat periodontitis (gum recession disease) in canines.

Key Points: 
  • YOKNEAM ILLIT, Israel, Sept. 22, 2022 /PRNewswire/ -- Israeli startup BioChange , which has developed a breakthroughtechnologyfortissue regeneration,was able to treat periodontitis (gum recession disease) in canines.
  • The use of BioChange's ReGum TM led to a 100% improvement in comparison to the standard-of-care treatment regimen, with a significant regeneration of periodontal tissue (including gum and bone tissues).
  • Periodontal disease is a widespread degenerative disease, which impacts far more than a person's gums and teeth.
  • There is now a significant body of evidence to support the link between periodontitis and life-threatening cardiovascular disease.

Frontera Therapeutics Receives Additional IND Clearance for its Lead Program FT-001

Retrieved on: 
Wednesday, September 21, 2022
Dai, Lists of diseases, Safety, Center for Drug Evaluation and Research, IRD, U.S. FDA, AAV, FDA, Food, Center, Visual impairment, Retinal degeneration (rhodopsin mutation), Ophthalmology, RPE65, RPE, Hematology, Occult macular dystrophy, Therapy, CDE, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Eye, CEO, Severe cognitive impairment, Retinal pigment epithelium, Neurology, CNS, Research, GLOBE, NMPA, Mutation, GMP, IRDS, Pharmaceutical industry, IND

Frontera previously announced that the U.S. Food and Drug Administration (FDA) also cleared an IND for FT-001 earlier this year in April.

Key Points: 
  • Frontera previously announced that the U.S. Food and Drug Administration (FDA) also cleared an IND for FT-001 earlier this year in April.
  • Inherited retinal degenerations or dystrophies are a heterogenous group of serious eye conditions that cause visual impairment that may lead to blindness.
  • This year, we have advanced our lead program, FT-001, and have received both U.S. FDA and China CDE IND clearances.
  • For additional information about Frontera Therapeutics, please visit the companys website at www.fronteratherapeutics.com .

Cognition Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 9, 2022
Lewy body, Intellectual property, Risk, Private Securities Litigation Reform Act, CEO, RPE, Dementia, Trial of the century, GLOBE, DLB, SPARC, National Institute, AAIC, SHINE, Research, Public expenditure, SHIMMER, Patient, Therapy, Cell, COVID-19, Company, Alzheimer's disease, Central nervous system, National Institute on Aging, Degenerative disease, ACTC, AMD, Neurodegeneration, NASDAQ, Securities & Exchange Commission of Pakistan, U.S. Securities and Exchange Commission, Retinal, ARVO, Retina, Philadelphia Managing Director's Office, Pharmaceutical industry, Lease, Cognition

PURCHASE, N.Y., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX) (the “Company” or “Cognition”), a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina, today reported financial results for the second quarter ended June 30, 2022 and provided recent business updates.

Key Points: 
  • The second quarter of 2022 has been characterized by optimistic advancements in our clinical trials and compelling data presentations, said Lisa Ricciardi, president and CEO of Cognition.
  • Presented data at ARVO 2022 conference held in May 2022 suggesting favorable acting mechanism of CT1812 for the treatment of dry AMD.
  • Research and development expenses for the second quarter ended June 30, 2022 were $9.1 million compared to $4.9 for the same period in 2021.
  • Net loss attributable to common stockholders for the second quarter ended June 30, 2022, was $5.8 million, or $(0.25) per share.

Sana Biotechnology Reports Second Quarter 2022 Financial Results and Business Updates

Retrieved on: 
Thursday, August 4, 2022
Serum, Survival, Risk, Social disruption, RPE, GLOBE, HIP, Cancer, Research, Degenerative disease, Patient, Biotechnology, Research and development, State Administrative Expenses, Development, Immunosuppression, Terminology, Disease, Primate, Hepatocyte, Gene, Technology, Potency (pharmacology), CD22, Contingency (philosophy), Safety, IND World's Fair Line, BCMA, Income, Retinal pigment epithelium, Cell, COVID-19, Drug development, ISSCR, AACR, SANA, Organization, ADA, IND, Company, NASDAQ, GAAP, Retinal, Administration, Information technology, Mobile phone, Pharmaceutical industry, Vaccine, Cryptocurrency, Online gambling, Reinsurance

SEATTLE, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on creating and delivering engineered cells as medicines, today reported financial results and business highlights for the second quarter 2022.

Key Points: 
  • We are pleased with the continued progress this quarter both across our platforms and with our product candidates.
  • Sana also presented data showing that HIP allogeneic regulatory T cells function and are able to evade immune detection in preclinical models.
  • These data provide a path for a potential safety strategy as well as validation of the mechanism of immune protection.
  • The Company has based these forward-looking statements largely on its current expectations, estimates, forecasts and projections about future events and financial trends that it believes may affect its financial condition, results of operations, business strategy and financial needs.

Worldwide Respiratory Protective Equipment Industry to 2027 - Featuring 3M, Alpha Pro Tech and Honeywell International Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, July 4, 2022
Medical Devices, Health, MSA Safety, Mesothelioma, Honeywell, ADF, Nose, COPD, Research, R, Personal protective equipment, ILC Dover, Mask, COVID-19, Growth, Industry, Gas, LP, PPE, Atmosphere, Mouth, Health, Mining, Lung cancer, Face, Textile, Awareness, Plant, 3M, Occupational asthma, RPE, Dangerous, Government, Chronic obstructive pulmonary disease, Potash, Pneumoconiosis

The respiratory protective equipment (RPE) refers to a kind of personal protective equipment (PPE) that safeguards the wearer from inhaling hazardous substances, dust particles and gases in the air.

Key Points: 
  • The respiratory protective equipment (RPE) refers to a kind of personal protective equipment (PPE) that safeguards the wearer from inhaling hazardous substances, dust particles and gases in the air.
  • These equipment are commonly used in chemicals, textiles and paper processing mills, along with metalworking plants and construction sites.
  • The competitive landscape of the industry has also been examined with some of the key players being 3M Company, Alpha Pro Tech Limited, E.D.
  • What is the structure of the global respiratory protective equipment market and who are the key players?